
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZC3HC1 (zinc finger C3HC-type containing 1) encodes an F-box-containing protein that functions as a component of an SCF-type E3 ubiquitin ligase complex. The complex regulates cell-cycle progression by targeting cyclin B1 for ubiquitin-mediated degradation, thereby controlling the transition from G2 phase to mitosis. ZC3HC1 therefore contributes to regulation of cell-cycle timing through targeted protein degradation.
THP-1 is a human monocytic leukemia cell line established from the peripheral blood of a 1-year-old male patient with acute monocytic leukemia at relapse. The cells exhibit monocytic characteristics, including expression of Fc and complement receptors, lysozyme production, esterase activity, and phagocytic capacity. THP-1 cells can be differentiated into macrophage-like cells under appropriate stimulation and are widely used as a model for studying monocyte/macrophage biology, immune responses, inflammation, differentiation, and host–pathogen interactions.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001282191
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?